ArticleJournal of endocrinological investigation2025
Prognostic role of the BRAF V600E variant in the preoperative biopsy in differentiated thyroid cancer.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence of thyroid carcinoma (TC) has increased worldwide, and the prognostic role of the BRAF V600E variant is controversial.
methodsThis study aims to define its prognostic role in TC, as defined in the preoperative period. This is a STROBE-compliant cohort study of patients with differentiated TC treated in a cancer center. Exposure was the presence of the BRAF V600E variant in the cellular blocks from the fine-needle aspiration biopsy; the outcome were the TC recurrence and recurrence-free survival (RFS).
resultsEighty-seven patients with TC were included; 65 were women (74.7%), 64 (73.6%) papillary TC and 55 (63.2%) had the BRAF V600E variant. Ten patients (11.5%) were low-, 33 (37.9%) intermediate-, and 44 (50.6%) high-risk. The BRAF V600E variant was associated with RFS in non-papillary subtypes. By bivariate analysis, the BRAF V600E variant was not clearly associated with recurrence. Nonetheless, by multivariate analysis, males (Hazard ratio [HR] 2.608, 95% Confidence interval [CI] 1.28-5.32), tumor size (HR 1.209; 95% CI 1.07-1.36), poor differentiation (HR 2.16; 95% CI 1.03-4.56), extrathyroidal invasion (HR 3.04; 95% CI 0.91-10.8), presence of BRAF V600E variant (HR 2.16; 95% CI 0.98-4.73) and adjuvant
conclusionThe BRAF V600E variant, determined by cytology in the preoperative setting was independently associated with decreased RFS in males, large tumors, poor grade and extrathyroidal invasion. This multivariate model could contribute to define risk in the preoperative setting to design treatment strategy.
Indexed as
Identifiers
40848225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.